SG11202004939SA - Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody - Google Patents

Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Info

Publication number
SG11202004939SA
SG11202004939SA SG11202004939SA SG11202004939SA SG11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA
Authority
SG
Singapore
Prior art keywords
biomarker
ligand
antibody
treatment
methods
Prior art date
Application number
SG11202004939SA
Inventor
Peter Peizhi Luo
Guizhong Liu
Fangyong Du
Original Assignee
Adagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Inc filed Critical Adagene Inc
Publication of SG11202004939SA publication Critical patent/SG11202004939SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202004939SA 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody SG11202004939SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/114247 WO2019104716A1 (en) 2017-12-01 2017-12-01 Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
PCT/CN2018/118631 WO2019105468A1 (en) 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Publications (1)

Publication Number Publication Date
SG11202004939SA true SG11202004939SA (en) 2020-06-29

Family

ID=66664325

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004939SA SG11202004939SA (en) 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Country Status (8)

Country Link
US (1) US20200377608A1 (en)
EP (1) EP3717010A4 (en)
JP (1) JP2021507877A (en)
CN (1) CN111344014A (en)
AU (1) AU2018377751A1 (en)
CA (1) CA3079479A1 (en)
SG (1) SG11202004939SA (en)
WO (2) WO2019104716A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019017628A2 (en) 2017-02-24 2020-07-07 Macrogenics, Inc. cd137 x ta binding molecule, pharmaceutical compositions, use of cd137 x ta binding molecule, cd137 binding molecule, use of cd137 binding molecule, her2 / neu binding molecule, use of her2 binding molecule / neu, and use of a composition
CN111511762A (en) 2017-08-21 2020-08-07 天演药业公司 anti-CD137 molecules and uses thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TWI841551B (en) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 Combination therapy with targeted 4-1bb (cd137) agonists
AR114284A1 (en) * 2018-04-13 2020-08-12 Hoffmann La Roche HER2 TARGETING ANTIGEN BINDING MOLECULES COMPOSING 4-1BBL
JP7432716B2 (en) * 2019-11-13 2024-02-16 合肥瀚科邁博生物技術有限公司 Molecules capable of binding to human 4-1BB and their applications
CA3177717A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer
WO2021226883A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer submission of sequence listing on ascii text file
AU2021297240A1 (en) * 2020-06-23 2023-01-19 Adagene Pte. Ltd. Combination therapy comprising anti-CD137 antibodies
GB202210965D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210957D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
CN109485727A (en) * 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
CN1294146C (en) * 2005-10-17 2007-01-10 山东大学 Polypeptide combined with T cell surface co-stimulation molecule CD137 and its use
ES2336873B1 (en) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT.
EP3082839A4 (en) * 2013-12-20 2017-08-09 National University of Singapore Differentiation therapy with cd137 ligand agonists
CA2977257A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
WO2017049452A1 (en) * 2015-09-22 2017-03-30 苏州丁孚靶点生物技术有限公司 Fully human antibody against human cd137 and use thereof
BR112018012138A2 (en) * 2015-12-17 2018-12-04 Novartis Ag pd-1 antibody molecules and uses thereof

Also Published As

Publication number Publication date
AU2018377751A1 (en) 2020-07-16
JP2021507877A (en) 2021-02-25
WO2019105468A8 (en) 2020-05-14
CN111344014A (en) 2020-06-26
EP3717010A1 (en) 2020-10-07
CA3079479A1 (en) 2019-06-06
US20200377608A1 (en) 2020-12-03
WO2019104716A1 (en) 2019-06-06
WO2019105468A1 (en) 2019-06-06
EP3717010A4 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
SG11202004939SA (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
IL288649A (en) Humanized anti-tau antibodies
SG11201605580RA (en) Antibodies directed against interleukin-33 (il-33)
IL272349A (en) Anti-cd137 antibodies
PT3285784T (en) Method for preparing a fecal microbiota sample
ZA201700824B (en) Carrier molecule for antigens
SG11201607030PA (en) Antibodies, uses & methods
IL252716A0 (en) Anti-csf1r antibodies for treating pvns
IL266564A (en) Methods for treating obesity with anti-angptl8 antibodies
SG11201701875YA (en) Methods for detecting ovarian cancer
ZA201608777B (en) Method for preparing methyl mercaptan
GB201905146D0 (en) Method for preparing aronatic hydrocarbons
PL3178803T3 (en) Method for preparing 2,3,3,3-tetrafluoropropene
SI3160984T1 (en) Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
PL3224225T3 (en) A process for preparing ethene
PT3224226T (en) Process for preparing ethene
GB2527129B (en) Method for preparing a ninhydrin reagent
EP3371592C0 (en) A method for quantifying therapeutic antibodies
GB201413950D0 (en) Antibodies, uses & methods
GB201400597D0 (en) Antibodies, uses & methods